These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Different clinical manifestations of hyperammonemic encephalopathy. Gomceli YB; Kutlu G; Cavdar L; Sanivar F; Inan LE Epilepsy Behav; 2007 Jun; 10(4):583-7. PubMed ID: 17412645 [TBL] [Abstract][Full Text] [Related]
4. [A case report of valproate encephalopathy]. Miyamoto T; Miyamoto M; Hirata K; Katayama S Rinsho Shinkeigaku; 1999 Oct; 39(10):1075-7. PubMed ID: 10655774 [TBL] [Abstract][Full Text] [Related]
5. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Latour P; Biraben A; Polard E; Bentué-Ferrer D; Beauplet A; Tribut O; Allain H Hum Psychopharmacol; 2004 Apr; 19(3):193-203. PubMed ID: 15079854 [TBL] [Abstract][Full Text] [Related]
6. [Alterations of the state of consciousness induced by valproic acid: 6 case reports]. Campostrini R; Paganini M; Boncinelli L; Zaccara G; Arnetoli G; Zappoli R Riv Patol Nerv Ment; 1983; 104(1):23-34. PubMed ID: 6431599 [TBL] [Abstract][Full Text] [Related]
7. [Valproate-caused encephalopathy]. Thygesen KS; Wolf P Ugeskr Laeger; 2005 Oct; 167(40):3793-4. PubMed ID: 16221398 [TBL] [Abstract][Full Text] [Related]
8. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Hamer HM; Knake S; Schomburg U; Rosenow F Neurology; 2000 Jan; 54(1):230-2. PubMed ID: 10636156 [TBL] [Abstract][Full Text] [Related]
9. Valproate-induced encephalopathy. Chen WT; Yen DJ; Yu HY; Liao KK Zhonghua Yi Xue Za Zhi (Taipei); 2001 Aug; 64(8):474-8. PubMed ID: 11720147 [TBL] [Abstract][Full Text] [Related]
10. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Hamed SA; Abdella MM Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440 [TBL] [Abstract][Full Text] [Related]
11. [Valproate-associated hyperammonemic encephalopathy. Report of one case]. Young P; Finn BC; Alvarez F; Bruetman JE; Trimarchi H Rev Med Chil; 2007 Nov; 135(11):1446-9. PubMed ID: 18259656 [TBL] [Abstract][Full Text] [Related]
12. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Chopra A; Kolla BP; Mansukhani MP; Netzel P; Frye MA Gen Hosp Psychiatry; 2012; 34(3):290-8. PubMed ID: 22305367 [TBL] [Abstract][Full Text] [Related]
14. [Hyperammonemia in valproate therapy in children and adolescents]. Laub MC Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461 [TBL] [Abstract][Full Text] [Related]
15. Topiramate increases the risk of valproic acid-induced encephalopathy. Noh Y; Kim DW; Chu K; Lee ST; Jung KH; Moon HJ; Lee SK Epilepsia; 2013 Jan; 54(1):e1-4. PubMed ID: 22691153 [TBL] [Abstract][Full Text] [Related]
16. [Report of three cases of hyperammonaemic encephalopathy associated with valproic acid due to possible synergism with phenobarbital and topiramate]. Cano-Zuleta A; Hernández-Ortíz OH; González-González CA; Amariles P Farm Hosp; 2012; 36(5):441-2. PubMed ID: 22266198 [No Abstract] [Full Text] [Related]
17. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Pylvänen V; Pakarinen A; Knip M; Isojärvi J Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693 [TBL] [Abstract][Full Text] [Related]